REGENXBIO Inc. (RGNX) shareholders
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Redmile Group, LLC Joint filing with Jeremy C. Green (9.90%), Redmile Biopharma Investments III, L.P. (7.40%) | 5,062,477 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 3,678,738 | 7.30% | 13G (passive) amendment | Mar 31, 2025 |
| JPMorgan Chase & Co. | 3,560,915 | 5.30% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RGNX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,397,440 | 9.69% | $76.64M | +614,632 | 0.00% |
| Redmile Group, LLC | 4,368,804 | 6.62% | $52.34M | – | 3.51% |
| State Street Corp | 2,971,173 | 4.50% | $35.59M | +239,688 | 0.00% |
| JPMorgan Chase & Co | 2,214,169 | 3.35% | $26.19M | −1,269,631 | 0.00% |
| Vanguard Capital Management LLC | 2,107,557 | 3.19% | $25.25M | +100,411 | 0.00% |
| Morgan Stanley | 1,953,237 | 2.96% | $23.40M | −112,920 | 0.00% |
| Goldman Sachs Group Inc | 1,421,453 | 2.15% | $17.03M | −418,010 | 0.00% |
| Aqr Capital Management LLC | 1,378,358 | 2.09% | $16.51M | +326,646 | 0.01% |
| Vanguard Portfolio Management LLC | 1,355,554 | 2.05% | $16.24M | +336,653 | 0.00% |
| Marshall Wace, Llp | 1,284,950 | 1.95% | $15.39M | New | 0.01% |
| Geode Capital Management, LLC | 1,241,296 | 1.88% | $14.87M | +103,798 | 0.00% |
| Integral Health Asset Management, LLC | 800,000 | 1.21% | $9.58M | −700,000 | 0.38% |
| Nuveen, LLC | 740,026 | 1.12% | $8.87M | +158,010 | 0.00% |
| Dimensional Fund Advisors LP | 731,586 | 1.11% | $8.76M | −278,795 | 0.00% |
| D. E. Shaw & Co., Inc. | 712,814 | 1.08% | $8.54M | +426,813 | 0.00% |
| Two Sigma Investments, LP | 669,808 | 1.01% | $8.02M | +114,916 | 0.01% |
| Citadel Advisors LLC | 669,023 | 1.01% | $8.01M | New | 0.00% |
| Stifel Financial Corp | 560,727 | 0.85% | $6.72M | +167,958 | 0.01% |
| Bank Of America Corp /De/ | 518,545 | 0.79% | $6.21M | +193,685 | 0.00% |
| 22NW, LP | 492,759 | 0.75% | $5.90M | – | 5.64% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 165 | 42M | 64.2% | 25 / 62 | 52 / 35 | 7M | 8M |
| Q1 2026 | 178 | 43M | 64.6% | 33 / 60 | 59 / 26 | 8M | 3M |
| Q4 2025 | 174 | 41M | 62.4% | 24 / 63 | 60 / 14 | 4M | 8M |
| Q3 2025 | 166 | 45M | 68.8% | 23 / 64 | 52 / 15 | 8M | 5M |
| Q2 2025 | 159 | 42M | 63.7% | 25 / 60 | 51 / 28 | 7M | 6M |
| Q1 2025 | 164 | 42M | 63.1% | 34 / 51 | 53 / 44 | 6M | 6M |
| Q4 2024 | 177 | 42M | 63.8% | 39 / 57 | 51 / 44 | 7M | 11M |
| Q3 2024 | 186 | 46M | 69.9% | 31 / 65 | 50 / 25 | 13M | 5M |
| Q2 2024 | 181 | 47M | 70.8% | 25 / 74 | 48 / 30 | 5M | 7M |
| Q1 2024 | 188 | 49M | 74.2% | 40 / 61 | 52 / 23 | 8M | 3M |
| Q4 2023 | 171 | 44M | 66.5% | 32 / 47 | 61 / 20 | 11M | 4M |
| Q3 2023 | 159 | 37M | 56.3% | 17 / 62 | 52 / 25 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
174 funds held RGNX in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RGNX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,958,976 | 2.97% | $23.47M | 0.22% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,496,139 | 2.27% | $17.92M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,270,455 | 1.92% | $15.22M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 855,170 | 1.30% | $8.29M | 0.20% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 629,843 | 0.95% | $7.55M | 0.29% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 564,476 | 0.86% | $6.76M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 527,935 | 0.80% | $5.12M | 0.02% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 467,248 | 0.71% | $5.60M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 378,118 | 0.57% | $4.53M | 0.03% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 339,957 | 0.51% | $2.38M | 0.05% | May 29, 2026 |
| iShares Biotechnology ETF | 336,179 | 0.51% | $4.03M | 0.04% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 322,770 | 0.49% | $3.87M | 0.07% | Jun 30, 2026 |
| Vanguard Market Neutral Fund | 281,985 | 0.43% | $3.38M | 0.57% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 246,936 | 0.37% | $1.73M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 242,468 | 0.37% | $1.70M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Curran Simpson | Chief Executive Officer, Director | 338,053 | 0.51% | Jul 6, 2026 |
| Craig Malzahn | Chief Technology Officer | 109,737 | 0.17% | Nov 3, 2026 |
| Mitchell Chan | Chief Financial Officer | 147,120 | 0.22% | Nov 3, 2026 |
| Patrick J. Christmas | Chief Strategy & Legal Officer | 240,690 | 0.36% | Nov 3, 2026 |
| Steve Pakola | Chief Medical Officer | 240,263 | 0.36% | Nov 3, 2026 |
| Olivier Danos | Chief Scientific Officer | 226,348 | 0.34% | Apr 4, 2025 |
| Gregory Austin Ciongoli | Director | 118,035 | 0.18% | Aug 27, 2026 |
| Daniel Tasse | Director | 28,861 | 0.04% | Jun 2, 2026 |
| George V. Migausky | Director | 28,861 | 0.04% | Jun 2, 2026 |
| Jean Bennett | Director | 28,861 | 0.04% | Jun 2, 2026 |
| Jennifer Zachary | Director | 31,871 | 0.05% | Jun 2, 2026 |
| Argeris N. Karabelas | Director | 28,861 | 0.04% | Jun 2, 2026 |
| David C. Stump | Director | 28,861 | 0.04% | Jun 2, 2026 |
| Kenneth T. Mills | Director | 495,925 | 0.75% | Jun 2, 2026 |
| Allan M. Fox | Director | 2,911,327 | 4.41% | Jun 2, 2026 |
| Alexandra Glucksmann | Director | 28,861 | 0.04% | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Craig Malzahn Chief Technology Officer | Nov 1, 2026 | Award | +27,777 | – | – | 109,737 |
| Mitchell Chan Chief Financial Officer | Nov 1, 2026 | Award | +24,305 | – | – | 147,120 |
| Steve Pakola Chief Medical Officer | Nov 1, 2026 | Award | +34,722 | – | – | 240,263 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Nov 1, 2026 | Award | +34,722 | – | – | 240,690 |
| Mitchell Chan Chief Financial Officer | Sep 1, 2026 | Tax withholding | −4,902 | $9.32 | $45.69K | 122,815 |
| Craig Malzahn Chief Technology Officer | Sep 1, 2026 | Tax withholding | −234 | $9.32 | $2.18K | 81,960 |
| Gregory Austin Ciongoli Director | Aug 27, 2026 | Buy | +53,407 | $9.36 | $499.89K | 118,035 |
| Gregory Austin Ciongoli Director | Aug 26, 2026 | Buy | +49,196 | $9.14 | $449.65K | 64,628 |
| Gregory Austin Ciongoli Director | Aug 25, 2026 | Award | +15,432 | – | – | 15,432 |
| Steve Pakola Chief Medical Officer | Aug 1, 2026 | Tax withholding | −7,468 | $9.69 | $72.36K | 205,541 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Aug 1, 2026 | Tax withholding | −4,699 | $9.69 | $45.53K | 205,968 |
| Steve Pakola Chief Medical Officer | Jul 2, 2026 | Option exercise | +2,161 | $7.86 | $16.99K | 215,170 |
| Steve Pakola Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −2,161 | $13.64 | $29.48K | 213,009 |
| Curran Simpson Chief Executive Officer, Director | Jul 1, 2026 | Tax withholding | −6,818 | $13.09 | $89.25K | 338,053 |
| Steve Pakola Chief Medical Officer | Jul 1, 2026 | Option exercise | +36,725 | $7.86 | $288.66K | 249,734 |
| Steve Pakola Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −36,725 | $12.86 | $472.28K | 213,009 |
| Curran Simpson Chief Executive Officer, Director | Jun 30, 2026 | Award | +1,453 | $10.18 | $14.79K | 344,871 |
| Steve Pakola Chief Medical Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −19,608 | $11.04 | $216.47K | 213,009 |
| Alexandra Glucksmann Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Allan M. Fox Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Argeris N. Karabelas Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Kenneth T. Mills Director | May 29, 2026 | Award | +9,807 | – | – | 495,925 |
| Jennifer Zachary Director | May 29, 2026 | Award | +9,807 | – | – | 31,871 |
| Daniel Tasse Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| David C. Stump Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Jean Bennett Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| George V. Migausky Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Steve Pakola Chief Medical Officer | May 11, 2026 | Sale(10b5-1 plan) | −15,309 | $11.02 | $168.71K | 232,617 |
| Steve Pakola Chief Medical Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −5,124 | $10.35 | $53.03K | 247,926 |
| Steve Pakola Chief Medical Officer | Feb 1, 2026 | Tax withholding | −5,267 | $11.16 | $58.78K | 253,050 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Feb 1, 2026 | Tax withholding | −4,700 | $11.16 | $52.45K | 210,667 |
| Kenneth T. Mills Director | Jan 27, 2026 | Option exercise | +225,000 | $13.09 | $2.95M | 707,871 |
| Kenneth T. Mills Director | Jan 27, 2026 | Tax withholding | −221,753 | $13.41 | $2.97M | 486,118 |
| Craig Malzahn Chief Technology Officer | Jan 6, 2026 | Award | +65,847 | – | – | 82,194 |
| Mitchell Chan Chief Financial Officer | Jan 6, 2026 | Award | +73,749 | – | – | 127,717 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Jan 6, 2026 | Award | +73,749 | – | – | 215,367 |
| Curran Simpson Chief Executive Officer, Director | Jan 6, 2026 | Award | +144,864 | – | – | 342,467 |
| Steve Pakola Chief Medical Officer | Jan 6, 2026 | Award | +65,847 | – | – | 258,317 |
| Steve Pakola Chief Medical Officer | Jan 2, 2026 | Tax withholding | −18,247 | $14.40 | $262.76K | 192,470 |
| Craig Malzahn Chief Technology Officer | Jan 2, 2026 | Tax withholding | −1,238 | $14.40 | $17.83K | 16,347 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Jan 2, 2026 | Tax withholding | −9,793 | $14.40 | $141.02K | 141,618 |
| Curran Simpson Chief Executive Officer, Director | Jan 2, 2026 | Tax withholding | −18,559 | $14.40 | $267.25K | 197,603 |
| Curran Simpson Chief Executive Officer, Director | Dec 31, 2025 | Award | +951 | $7.00 | $6.66K | 343,418 |
| Curran Simpson Chief Executive Officer, Director | Oct 9, 2025 | Sale(10b5-1 plan) | −20,811 | $12.62 | $262.63K | 216,162 |
| Curran Simpson Chief Executive Officer, Director | Sep 29, 2025 | Sale(10b5-1 plan) | −7,624 | $10.03 | $76.47K | 236,973 |
| Curran Simpson Chief Executive Officer, Director | Sep 10, 2025 | Sale(10b5-1 plan) | −7,734 | $10.02 | $77.49K | 244,597 |
| Craig Malzahn Chief Technology Officer | Sep 1, 2025 | Tax withholding | −234 | $8.93 | $2.09K | 17,585 |
| Mitchell Chan Chief Financial Officer | Sep 1, 2025 | Tax withholding | −4,901 | $8.93 | $43.77K | 53,968 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Aug 1, 2025 | Tax withholding | −4,699 | $8.19 | $38.48K | 151,411 |
| Curran Simpson Chief Executive Officer, Director | Jul 1, 2025 | Tax withholding | −4,701 | $8.23 | $38.69K | 252,331 |
| Jennifer Zachary Director | May 30, 2025 | Award | +7,768 | – | – | 22,064 |
| George V. Migausky Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Kenneth T. Mills Director | May 30, 2025 | Award | +7,768 | – | – | 482,871 |
| Daniel Tasse Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Argeris N. Karabelas Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Allan M. Fox Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Jean Bennett Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Alexandra Glucksmann Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| David C. Stump Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Kenneth T. Mills Director | May 12, 2025 | Sale(10b5-1 plan) | −20,602 | $7.91 | $162.96K | 475,103 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Regenxbio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,999 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen J. Pakola Officer | Jul 1, 2026 | 43,206 | $517.61K | Jul 1, 2026 | Exercise of Stock Options |
| Stephen Pakola Officer | May 11, 2026 | 34,917 | $368.37K | May 11, 2026 | Restricted Stock Units |
| Stephen J Pakola Officer | Mar 10, 2026 | 5,124 | $53.19K | Mar 10, 2026 | Restricted Stock Units |
| Curran Simpson Director, Officer | Oct 9, 2025 | 20,811 | $254.31K | Oct 9, 2025 | Restricted Stock Units |
| Curran Simpson Director, Officer | Sep 10, 2025 | 15,358 | $151.89K | Sep 10, 2025 | Restricted Stock Units |
| Kenneth T. Mills Director | May 12, 2025 | 20,602 | $154.93K | May 12, 2025 | Exercise of Stock Options |
| Vittal Vasista Officer | Dec 30, 2024 | 20,041 | $148.50K | Dec 30, 2024 | Previously Exercised Stock Options |
| Argeris N. Karabelas Director | Aug 1, 2024 | 31,000 | $441.75K | Aug 1, 2024 | Exercise of Stock Options |
| Curran Simpson Director, Officer | Jul 29, 2024 | 25,106 | $359.77K | Jul 29, 2024 | Restricted Stock Units |
| Argeris N. Karabelas Director | Jul 1, 2024 | 30,000 | $351.00K | Jul 1, 2024 | Exercise of Stock Options |
| Kenneth T. Mills Director, Officer | May 14, 2024 | 45,000 | $708.30K | May 14, 2024 | Exercise of Stock Options |
| Stephen J Pakola Officer | Mar 5, 2024 | 12,878 | $275.07K | Mar 5, 2024 | Exercise of Stock Options |
| Kenneth T. Mills Director, Officer | Jan 16, 2024 | 90,000 | $1.36M | Jan 16, 2024 | Exercise of Stock Options |
| Stephen J Pakola Officer | Jan 3, 2024 | 17,237 | $316.13K | Jan 3, 2024 | Restricted Stock Units |
| Kenneth T. Mills Director, Officer | Dec 19, 2023 | 45,000 | $877.95K | Dec 19, 2023 | Exercise of Stock Options |
Congress trades
2 trades in Regenxbio reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Peter Welch VT00 | Sold | Nov 8, 2019 | $1K–15K | Nov 14, 2019 |
| Peter Welch VT00 | Bought | Oct 22, 2019 | $1K–15K | Nov 14, 2019 |
See a number that looks wrong?